Want to see LNSR full AI Analyst Report?
LNSR Stock Chart & Stats
$5.60
-$0.23(-4.11%)
At close: 4:00 PM EDT
$5.60
-$0.23(-4.11%)
Day’s Range― - ―
52-Week Range$4.95 - $13.20
Previous Close$5.37
Volume49.28K
Average Volume (3M)58.95K
Market Cap
$60.64M
Enterprise Value$94.77
Total Cash (Recent Filing)$13.49M
Total Debt (Recent Filing)$2.57M
Price to Earnings (P/E)5.1
Beta0.98
Next Earnings
Aug 06, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding12,104,328
10 Day Avg. Volume51,870
30 Day Avg. Volume58,950
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-5.34
Price to Sales (P/S)2.38
P/FCF Ratio-9.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.50Price Target Upside51.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.79
Revenue Forecast (FY)$60.65M
Bulls Say, Bears Say
Bulls Say
High Recurring Revenue Mix & GrowthA very high recurring-revenue mix (≈94%) with 9% YoY growth provides durable, predictable cash flows tied to procedures and service. This reduces reliance on volatile capital sales, supports margin stability, and gives management a steadier revenue base to scale service, installs and long-term adoption.
Installed Base Expansion & Procedure VolumesAn expanding installed base (up 12% YoY) and rising procedure volumes increase unit utilization and recurring consumables/service revenue over time. A larger installed footprint also strengthens clinical adoption, network effects, and future capital replacement/upgrade demand, underpinning sustainable growth.
Product Roadmap & R&D FocusA clear product roadmap aimed at new corneal applications and enhanced automation deepens the platform's clinical utility and differentiation. Continued technical innovation can drive higher procedure share, justify recurring consumable/service spend, and protect competitive positioning long term.
Bears Say
Weak Cash Generation / Rising Cash BurnSustained negative operating and free cash flow (TTM ~ -$12.2M) indicates cash burn that erodes liquidity absent improved profitability or financing. With modest cash on hand and planned rebuild of sales/service capacity, funding pressure could constrain growth investments and slow recovery over multiple quarters.
Operating Losses & Weak Earnings QualityUnderlying operating profitability is weak (negative EBIT/EBITDA margins) while GAAP net income was materially boosted by one-time, noncash items. This gap undermines earnings quality and makes current reported profits less repeatable, complicating forecasting and capital allocation decisions.
System Placement Weakness & International HeadwindsA sharp decline in capital-system placements reduces near-term upside to recurring revenue and delays installed-base-driven growth. Distributor reactivation and international shipments are expected to take several quarters, creating execution and timing risk for the company’s recovery roadmap.
LENSAR News
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $4.95 and its highest was $13.20 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $60.64M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on May 08, 2026. The company reported $1.56 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Undervalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate is -0.17.
How many shares outstanding does LENSAR have?
LENSAR has 12,104,328 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of $1.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.839%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENSAR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (51.79% Upside)
$8.50 (51.79% Upside)
Hedge Fund Trend
Increased
By 172.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LNSR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but stabilizing picture: operational fundamentals improved with durable recurring revenue growth (+9% YoY to $12.6M), installed-base expansion (+12% to ~440 systems) and rising procedure volumes (~54k). At the same time, near-term financials show weaknesses driven by a sharp decline in system revenue (~$0.8M vs $2.6M prior), a negative adjusted EBITDA (-$0.31M), modest cash ($13.5M), and one-time/non‑cash items that materially inflated GAAP net income. Management reports growing commercial momentum post-transaction (demos, distributor POs, product roadmap) but acknowledges it will take several quarters to rebuild international placements and fully restore prior growth rates. Overall, the call balances encouraging operational signs and strategic clarity against measurable near-term financial and timing challenges.View all LNSR earnings summariesLNSR Stock 12 Month Forecast
Average Price Target
$8.50
▲(51.79% Upside)
Technical Analysis
Ownership Overview
42.73% Insiders
7.95% Mutual Funds
1.73% Other Institutional Investors
44.03% Public Companies and
Individual Investors